Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 23 Sep 2016
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms SUSTRENIM
- 13 Sep 2016 Planned initiation date changed from 1 Mar 2016 to 1 Dec 2016.
- 24 Feb 2016 Planned End Date changed from 1 Feb 2021 to 1 Feb 2024 as reported by ClinicalTrials.gov record.
- 24 Feb 2016 Planned primary completion date changed from 1 Feb 2021 to 1 Feb 2023 as reported by ClinicalTrials.gov record.